DEVELOPMENT OF A HIGHLY COMPLIANT VASCULAR GRAFT

高度顺应性血管移植物的开发

• 批准号: 3508462
• 负责人: PHILIP LITWAK
• 金额: $ 26.35万
• 依托单位: THORATEC LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-05-01 至 1989-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3508462
• 关键词: angiography; antithrombogenic surface; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; blood vessel prosthesis; carotid artery; coronary bypass; elasticity; histopathology; implant; microscopy; polyurethanes; radionuclide imaging /scanning; radiotracer; scanning electron microscopy; surface property; technetium; tensile strength

A new highly compliant vascular graft has been fabricated from a unique polyurethane material. Prototype grafts have demonstrated excellent blood compatibility and no perigraft reaction. Maximum thickness of endothelial and subintimal tissues bridging the anastomoses have been 15-20 microns and in some cases only a continuous monolayer of endothelial cells has been found. Bulk and surface properties required of the material have been decoupled and developed independently in two separate materials. The final polymer consists of a blend of surface active copolymers and bulk material to produce a formulation optimized for this specific use. Production of 4 mm diameter vascular grafts will utilize our patented process for fabrication of multi-layered tubing. These grafts will be tested both in vivo and in vitro. In vitro testing will include compliance, burst strength, kink radius, elongation and suture pullout strength. Grafts will be tested before and after sterilization. Life testing will also be accomplished. In vivo evaluation will be accomplished by implanting 8 cm lengths in the carotid arteries of mature goats and as aorto-coronary bypasses in calves. 99m Technetium scanning will be used to determine patency. Explanted grafts will be resubjected to the in vitro test protocol as well as SEM and standard microscopic examination.

一种新的高度顺应性的血管移植物已经从一种独特的 聚氨酯材料。 原型移植显示出良好的血液 相容性和无移植物周围反应。 最大内皮厚度 和内膜下组织桥接动脉粥样硬化已经为15-20微米， 在某些情况下， found. 材料所需的体积和表面性质已被解耦 并在两种不同的材料中独立开发。 最终聚合物 由表面活性共聚物和本体材料的共混物组成， 生产针对该特定用途优化的制剂。 生产4毫米直径的血管移植物将利用我们的专利 制造多层管的方法。 这些移植物 在体内和体外都进行了测试。 体外测试将包括 顺应性、爆破强度、扭结半径、伸长率和缝线拔出 实力 将在灭菌前后对移植物进行试验。 生活 测试也将完成。 体内评价将通过将8 cm长度植入 成熟山羊的颈动脉和小牛的冠状动脉旁路。 将使用99 m锝扫描确定通畅性。 取出 移植物将再次接受体外试验方案以及SEM， 标准显微镜检查。